<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Abuse Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Abuse Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance abuse treatment</journal-title></journal-title-group><issn pub-type="ppub">0740-5472</issn><issn pub-type="epub">1873-6483</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10664516</article-id><article-id pub-id-type="pmcid-ver">PMC10664516.1</article-id><article-id pub-id-type="pmcaid">10664516</article-id><article-id pub-id-type="pmcaiid">10664516</article-id><article-id pub-id-type="manuscript-id">NIHMS1943110</article-id><article-id pub-id-type="pmid">36327615</article-id><article-id pub-id-type="doi">10.1016/j.jsat.2022.108921</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1943110</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1943110</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Smart</surname><given-names initials="R">Rosanna</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="JY">Joo Yeon</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kennedy</surname><given-names initials="S">Susan</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="L">Lu</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Allen</surname><given-names initials="L">Lindsay</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crane</surname><given-names initials="D">Dushka</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mack</surname><given-names initials="A">Aimee</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mohamoud</surname><given-names initials="S">Shamis</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pauly</surname><given-names initials="N">Nathan</given-names></name><xref rid="A8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perez</surname><given-names initials="R">Rosa</given-names></name><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donohue</surname><given-names initials="J">Julie</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib></contrib-group><aff id="A1"><label>a</label>Drug Policy Research Center, RAND Corporation, 1776 Main Street, PO Box 2138, Santa Monica, CA 90407-2138, United States of America</aff><aff id="A2"><label>b</label>Department of Health Policy and Management, University of Pittsburgh, 130 DeSoto Street, Crabtree Hall A635, Pittsburgh, PA 15261, United States of America</aff><aff id="A3"><label>c</label>AcademyHealth, 1666 K Street NW, Suite 1100, Washington, DC 20006, United States of America</aff><aff id="A4"><label>d</label>Department of Biostatistics, University of Pittsburgh, 130 DeSoto Street, Pittsburgh, PA 15261, United States of America</aff><aff id="A5"><label>e</label>Department of Emergency Medicine, Buehler Center for Health Policy &amp; Economics, Northwestern University, 750 N. Lake Shore Drive, Evanston, IL 60611, United States of America</aff><aff id="A6"><label>f</label>Government Resource Center, The Ohio State University, 150 Pressey Hall, 1070 Carmack Road, Columbus, OH 43210, United States of America</aff><aff id="A7"><label>g</label>The Hilltop Institute, University of Maryland Baltimore County, Sondheim Hall, Third Floor, 1000 Hilltop Circle, Baltimore, MD 21250, United States of America</aff><aff id="A8"><label>h</label>Manatt Health Strategies, 151 N Franklin Street, Suite 2600, Chicago, IL 60606, United States of America</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author at: 1776 Main Street, PO Box 2138, Santa Monica, CA 90407-2138, United States of America. <email>rsmart@rand.org</email> (R. Smart).</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2022</year></pub-date><volume>144</volume><issue-id pub-id-type="pmc-issue-id">449562</issue-id><fpage>108921</fpage><lpage>108921</lpage><pub-history><event event-type="nihms-submitted"><date><day>17</day><month>11</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>22</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>22</day><month>11</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 16:25:15.287"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1943110.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">The opioid crisis is transitioning to a polydrug crisis, and individuals with co-occurring substance use disorder (SUDs) often have unique clinical characteristics and contextual barriers that influence treatment needs, engagement in treatment, complexity of treatment planning, and treatment retention.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">Using Medicaid data for 2017&#8211;2018 from four states participating in a distributed research network, this retrospective cohort study documents the prevalence of specific types of co-occurring SUD among Medicaid enrollees with an opioid use disorder (OUD) diagnosis, and assesses the extent to which different SUD presentations are associated with differential patterns of MOUD and psychosocial treatments.</p></sec><sec id="S3"><title>Results:</title><p id="P3">We find that more than half of enrollees with OUD had a co-occurring SUD, and the most prevalent co-occurring SUD was for &#8220;other psychoactive substances&#8221;, indicated among about one-quarter of enrollees with OUD in each state. We also find some substantial gaps in MOUD treatment receipt and engagement for individuals with OUD and a co-occurring SUD, a group representing more than half of individuals with OUD. In most states, enrollees with OUD and alcohol, cannabis, or amphetamine use disorder are significantly less likely to receive MOUD compared to enrollees with OUD only. In contrast, enrollees with OUD and other psychoactive SUD were significantly more likely to receive MOUD treatment. Conditional on MOUD receipt, enrollees with co-occurring SUDs had 10 % to 50 % lower odds of having a 180-day period of continuous MOUD treatment, an important predictor of better patient outcomes. Associations with concurrent receipt of MOUD and behavioral counseling were mixed across states and varied depending on co-occurring SUD type.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">Overall, ongoing progress toward increasing access to and quality of evidence-based treatment for OUD requires further efforts to ensure that individuals with co-occurring SUDs are engaged and retained in effective treatment. As the opioid crisis evolves, continued changes in drug use patterns and populations experiencing harms may necessitate new policy approaches that more fully address the complex needs of a growing population of individuals with OUD and other types of SUD.</p></sec></abstract><kwd-group><kwd>Medicaid</kwd><kwd>Polysubstance use</kwd><kwd>Medication treatment for opioid use disorder</kwd><kwd>Substance use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>